MAVYRET is a prescription medication used to treat chronic hepatitis C virus (HCV) infection [1]. It is a combination therapy that targets the HCV virus directly [1].
How does Mavyret work against Hepatitis C?
MAVYRET combines two active ingredients: glecaprevir and pibrentasvir [1]. Glecaprevir is an NS3/4A protease inhibitor, and pibrentasvir is an NS5A inhibitor [1]. These drugs work together to block the virus from replicating at different stages of its life cycle [1]. This dual-action approach is designed to be highly effective in clearing the HCV infection [1].
What types of Hepatitis C does Mavyret treat?
MAVYRET is approved to treat chronic hepatitis C virus genotypes 1, 2, 3, 4, 5, and 6 [1]. It is used in adults who have not been treated for hepatitis C before or who have been treated with other direct-acting antiviral medications [1]. The specific treatment regimen and duration depend on the genotype of the virus and whether there is evidence of cirrhosis [1].
How long is the Mavyret treatment course?
The duration of MAVYRET treatment varies. For most patients with genotypes 1, 2, 3, 4, 5, or 6 who have not previously been treated for HCV and do not have cirrhosis, the treatment course is 8 weeks [1]. For patients with certain genotypes or those with cirrhosis, the treatment course may be extended to 16 weeks [1].
What are the common side effects of Mavyret?
The most common side effects reported during MAVYRET treatment include headache and fatigue [1]. Less common side effects can also occur [1]. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].
Is Mavyret available as a generic?
As of now, MAVYRET is not available as a generic medication [2]. Patents are in place that protect the exclusivity of the drug [2]. Information on patent expiry and potential generic entry can be found on sites like DrugPatentWatch.com [2].
When does Mavyret's patent protection expire?
Patent exclusivity for MAVYRET is determined by various patents filed by its manufacturer. DrugPatentWatch.com tracks these patent landscapes, which can indicate potential dates for generic competition to enter the market [2]. These dates can be complex and subject to legal challenges or extensions [2].